Skip to main content

Moderna, Inc. Europe revenue

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

Europe revenue at Moderna, Inc. came to $53.0M for the fiscal year to 31 Dec 2025, down 91.1% from a year earlier.

As Moderna, Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 20 Feb 2026.

By fiscal year

$5.0MDec 2019$33.0MDec 2020$6.8BDec 2021$6.8BDec 2022$1.4BDec 2023$598.0MDec 2024$53.0MDec 2025
Moderna, Inc. Europe revenue, every reported period
Period endingEurope revenueChange on a yearFiled
31 Dec 2025$53.0Mdown 91.1%20 Feb 2026
31 Dec 2024$598.0Mdown 55.9%21 Feb 2025
31 Dec 2023$1.4Bdown 80.1%23 Feb 2024
31 Dec 2022$6.8Bdown 0.5%24 Feb 2023
31 Dec 2021$6.8B—25 Feb 2022
31 Dec 2020$33.0Mup 560.0%26 Feb 2021
31 Dec 2019$5.0M—27 Feb 2020

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Moderna, Inc.: COVID revenue · Stand-ready manufacturing revenue · RSV revenue · Collaboration Arrangement, Including Arrangements With Affiliate revenue · Grant revenue · United States revenue · Rest of world revenue · financial statements

Every KPI and segment of MRNA, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.